Therapy News and Research

RSS

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

6 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Study opens door to possible treatments for variety of mitochondrial diseases

By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria-the energy factories within cells. Doctors might someday use the approach to treat a variety of mitochondrial diseases, including the degenerative eye disease Leber hereditary optic neuropathy. The research, published online today in Nature Medicine, was funded by the National Eye Institute, a part of the National Institutes of Health.

5 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Life Care’s thoughts on neck pain from cervical herniated disc

Thoughts on neck pain from a Cervical Herniated Disc from Life Care Solutions Group's Sacramento Injury Lawyer, Dr. Greg Vigna.

3 Aug 2013

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

Prothrombin complex concentrates are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly used therapy.

3 Aug 2013

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.

3 Aug 2013

Necrostatin-1: A substance which counteracts several of aluminum's neurotoxic effects

New Studies in Mice Support Toxic Role of Aluminum in Neurodegenerative Conditions, According to Report in Restorative Neurology and Neuroscience

3 Aug 2013

IQWiG dossier assessment finds no added benefit of lixisenatide

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.

3 Aug 2013

Atossa Genetics: Many American women still not aware of breast cancer risk

Virtually all American women are aware that the pink ribbon is the symbol of breast cancer awareness. Despite this near-universal recognition, it is still a sad fact that plenty of women do not truly appreciate the extent to which they are at risk for breast cancer.

3 Aug 2013

HTR3 variants associated with effectiveness of ondansetron treatment for alcohol dependence

An experimental treatment for alcohol dependence works better in individuals who possess specific combinations of genes that regulate the function and binding of serotonin, a brain chemical affected by the treatment, according to a study supported by the National Institutes of Health. A report of the finding appears online in the American Journal of Psychiatry.

3 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

Toshiba receives order from NIRS for carbon ion radiotherapy system

Toshiba Corporation today announced that it has received an order from Japan's National Institute of Radiological Sciences (NIRS) for the world's first rotating gantry irradiation system with superconducting magnets for a carbon ion radiotherapy system. The system will be installed in a new radiotherapy room that NIRS is constructing at its facility in Chiba, east of Tokyo, in March 2015.

2 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.

2 Aug 2013

International meeting to focus on carbon ion radiotherapy for cancer patients

Cancer experts from around the world are converging in Denver on Thursday and Friday to analyze the success of cutting-edge radiation therapies, and to determine how one promising treatment option could be delivered for the first time to cancer patients in the United States.

2 Aug 2013

Therapy News and Research

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

Study opens door to possible treatments for variety of mitochondrial diseases

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Life Care’s thoughts on neck pain from cervical herniated disc

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Necrostatin-1: A substance which counteracts several of aluminum's neurotoxic effects

IQWiG dossier assessment finds no added benefit of lixisenatide

Atossa Genetics: Many American women still not aware of breast cancer risk

HTR3 variants associated with effectiveness of ondansetron treatment for alcohol dependence

Added benefit of thyroid cancer drug vandetanib not proven

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Toshiba receives order from NIRS for carbon ion radiotherapy system

ImmunoGen reports net loss of $21.9 million in Q4 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

International meeting to focus on carbon ion radiotherapy for cancer patients

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News